• DMG-PEG2000-NH2 for LNP Bioconjugation

  2026-09-12

  DMG-PEG2000-NH2 combines a PEG2000 spacer, a DMG lipid anchor, and a reactive amine for practical liposome, LNP, and biomolecule-conjugation workflows. This guide connects formulation design with assay controls, troubleshooting, and translational interpretation without overstating evidence from unrelated disease models.

• DMXAA (Vadimezan): Reliable Assay Workflows

  2026-09-11

  Learn how DMXAA (Vadimezan), SKU A8233, can be integrated into reproducible viability, apoptosis, and angiogenesis workflows. This scenario-based guide connects its documented DTD and VEGFR2-related activities with practical decisions about solubility, controls, dose selection, and supplier reliability.

• Gamithromycin PK/PD Targets in Piglet S. suis

  2026-09-11

  Wang et al. defined Streptococcus suis-specific pharmacodynamic targets for Gamithromycin in piglets and showed that serum exposure, rather than MIC alone, strongly influences apparent activity. The study links AUC24h/MIC to bacterial response, estimates a PK/PD cutoff, and provides a quantitative basis for dose-optimization studies without treating the simulated dose as a universal clinical recommendation.

• Firefly Luciferase mRNA as a Delivery Probe

  2026-09-10

  Firefly Luciferase mRNA can do more than report protein expression: it can reveal how formulation, cell targeting, and transcript design shape mRNA delivery. This article explains how to use 5-moUTP modified mRNA to interpret spatially controlled delivery experiments with greater mechanistic precision.

• Cy5-UTP Workflows for RNA Probe Synthesis

  2026-09-10

  Cy5-UTP enables direct, far-red RNA visualization for FISH, dual-color arrays, and labeled delivery studies without secondary staining. This guide connects practical RNA probe synthesis with charge- and cell-state-aware nanoparticle experiments, while separating validated product specifications from workflow recommendations.

• Degarelix acetate: Applied Research Workflows

  2026-09-09

  Degarelix acetate provides a rapid, selective way to interrogate GnRH signaling, pituitary hormone regulation, and androgen-dependent prostate cancer models. This guide translates receptor pharmacology and a recent neoadjuvant study into practical assay design, dosing logic, and troubleshooting steps.

• Substance P Workflows for Pain and Inflammation

  2026-09-09

  Build more reproducible Substance P experiments with controlled peptide handling, receptor-focused dose and time courses, and orthogonal spectral quality checks. The workflow connects pain transmission research with inflammation mediator and immune response modulation assays while clearly separating biological evidence from analytical troubleshooting.

• Chenodeoxycholic Acid: A Smarter FXR Assay Strategy

  2026-09-08

  Chenodeoxycholic Acid (CDCA) is a mechanistically informative FXR activator for connecting bile acid sensing with transcriptional and injury-response phenotypes. This guide presents an assay-design framework that emphasizes causal validation, exposure control, and interpretation across cholesterol metabolism research and renal models.

• SB-505124 hydrochloride: Reliable Cell Assays

  2026-09-08

  A scenario-based guide to using SB-505124 hydrochloride (SKU A3799) in viability, fibrosis, signaling, and mechanobiology workflows. It connects documented ALK4/5/7 potency, formulation constraints, pathway controls, and vendor-selection considerations to more interpretable laboratory results.

• Digoxin Research: Cardiac, Antiviral, and TED Models

  2026-09-07

  Digoxin connects Na+/K+ ATPase inhibition with cardiac contractility studies, cell-type-specific chikungunya experiments, and a new HIF-1α-focused thyroid eye disease workflow. This guide translates those findings into practical assay design, dosing, controls, and troubleshooting strategies.

• Perospirone: Receptor-to-Channel Pharmacology

  2026-09-07

  Perospirone, also known as SM-9018 free base, is a mechanistically useful probe for studying serotonergic–dopaminergic signaling and vascular Kv1.5 channel modulation. This evidence-focused guide explains how to interpret its receptor affinity, newly reported ion-channel activity, and cross-domain research value without conflating distinct assay systems.

• Recombinant Annexin V for Apoptosis Detection

  2026-09-05

  Brumatti, Sheridan, and Martin describe an integrated workflow for expressing soluble polyhistidine-tagged annexin V in Escherichia coli, purifying it by nickel affinity chromatography, and converting it into a fluorescent probe for phosphatidylserine exposure. The method provides a practical route to flow-cytometric and microscopic apoptosis assays while clarifying why annexin V signal should be interpreted alongside membrane-integrity and biological controls.

• Digoxin, HIF-1α, and Thyroid Eye Disease Fibrosis

  2026-09-04

  A 2026 Biochemical and Biophysical Research Communications pre-proof identifies HIF-1α as a mediator linking hypoxia with inflammatory and fibrotic activation in thyroid eye disease. It further shows that low-nanomolar Digoxin suppresses HIF-1α-associated STAT3 signaling, inflammatory gene expression, extracellular-matrix remodeling, and GSDME-related pyroptosis in patient-derived orbital fibroblast models.

• Cefodizime: Evidence from a 1992 Clinical Review

  2026-09-04

  Barradell and Brogden’s review integrated microbiology, pharmacokinetics, host-defense observations, and clinical trial data to characterize Cefodizime as a broadly active third-generation cephalosporin antibiotic. Its main contribution was showing how prolonged exposure and possible immune effects could help explain clinical performance that appeared stronger than susceptibility data alone predicted, while also identifying important limits in the evidence.

• AM251 Workflows for CB1 Signaling Research

  2026-09-03

  AM251 is a nanomolar CB1 receptor antagonist for separating receptor-dependent cannabinoid effects from broader neuronal, metabolic, and cell-cycle responses. This practical guide connects the compound to pain-affect assays, obesity treatment research, and apoptosis assays while emphasizing solvent control, exposure design, and mechanistic validation.

8097 records 1/540 page Next 12345 下5页 Last page